Maintained strong cash position with approximately $325.0 million in cash and cash equivalents, expected to fund operations into 2028
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study
- Sionna Therapeutics Advances Phase 1 Study for Cystic Fibrosis Treatment
- Sionna Therapeutics announces initiation of PreciSION CF Phase 2a trial
- Sionna Therapeutics initiated with a Buy at Freedom Capital
- Sionna Therapeutics appoints Caroline Stark Beer as CBO